ERBB2 and breast cancer: Taken together, our data indicate that the erbB3 blocking Ab MM-121 significantly enhances trastuzumab-induced growth inhibition in two erbB2+ breast cancer cell lines and exhibits potential to overcome trastuzumab resistance mainly through inactivation of the erbB3/PI-3K/Akt signaling.